Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of Subcutaneous Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C

NCT01194037 is registered in ClinicalTrials.gov with HanAll BioPharma Co., Ltd. as lead sponsor.

NCT NCT01194037
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01194037 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a, Open-label,Randomized, Safety, Tolerability, Dose Finding, PK/PD, and Preliminary Efficacy Study of Subcutaneous Hanferon™ in Combination With Ribavirin in Treatment-naïve Subjects With Genotype 1 Hepatitis C
Lead sponsor
HanAll BioPharma Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
June 23, 2011
Completion date
November 28, 2011
Enrollment
30 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis c infection, genotype 1